ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years
Matthew J. Reilley
Matched on ORCID iD 0000-0002-4725-0459; OpenAlex author ID A5081272862. Sources: ClinicalTrials.gov.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 1 (principal investigator on 1)
- Grants
- 0
- Labs led
- 0
- Collaborators
- 36
2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 1 trial
Papers 4
- PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-1444↗
- A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. First author DOI 10.1158/1078-0432.ccr-24-0499↗
- Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline r… Co-author DOI 10.1136/jitc-2023-007586↗
- Using Graph Representation Learning to Predict Salivary Cortisol Levels in Pancreatic Cancer Patients. Co-author DOI 10.1007/s41666-021-00098-4↗
Trials 1
Closest collaborators
The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Todd W. Bauer · 3 shared papers, 2021–2024 · strength 0.43
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Paper Using Graph Representation Learning to Predict Salivary Cortisol Levels in Pancreatic Cancer Patients. DOI 10.1007/s41666-021-00098-4↗
- Craig Lee Slingluff · 2 shared papers, 2023–2024 · strength 0.30
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Matthew H. G. Katz · 2 shared papers, 2023–2024 · strength 0.30
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Victoire Cardot‐Ruffino · 2 shared papers, 2023–2024 · strength 0.30
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Andressa Dias Costa · 2 shared papers, 2023–2024 · strength 0.30
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Chee‐Chee Stucky · 2 shared papers, 2023–2024 · strength 0.30
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Rawad Elias · 2 shared papers, 2023–2024 · strength 0.30
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Nipun B. Merchant · 2 shared papers, 2023–2024 · strength 0.30
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Brian Matthew Wolpin · 2 shared papers, 2023–2024 · strength 0.30
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Osama E. Rahma · 2 shared papers, 2023–2024 · strength 0.30
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Tanios Bekaii‐Saab · 2 shared papers, 2023–2024 · strength 0.30
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Jonathan Andrew Nowak · 2 shared papers, 2023–2024 · strength 0.30
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Stephanie K. Dougan · 2 shared papers, 2023–2024 · strength 0.30
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Thomas E. Clancy · 1 shared paper, 2024 · strength 0.16
- Jiping Wang · 1 shared paper, 2024 · strength 0.16
- Lestat R. Ali · 1 shared paper, 2024 · strength 0.16
- Thomas Adam Abrams · 1 shared paper, 2024 · strength 0.16
- Joseph Douglas Mancias · 1 shared paper, 2024 · strength 0.16
- Michael James Overman · 1 shared paper, 2024 · strength 0.16
- Nick Pavlakis · 1 shared paper, 2024 · strength 0.16
- Mariano Ponz‐Sarvisé · 1 shared paper, 2024 · strength 0.16
- Niharika B. Mettu · 1 shared paper, 2024 · strength 0.16
- Adnan M. Nagrial · 1 shared paper, 2024 · strength 0.16
- David Robert Spigel · 1 shared paper, 2024 · strength 0.16
- Andrew L. Coveler · 1 shared paper, 2024 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.